Organon & Co | OGN - 应收帐款人





应收帐款人 更改 日
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Celltrion KRW 2.01T 39.71B 2026-03
Cspc Pharmaceutical CNY 8.79B 64.64M 2025-12
Deva Holding AS TRY 3.03B 343.23M 2023-09
Dianthus Therapeutics USD 1.23M 1.18M 2026-03
Divis Laboratories Ltd INR 29.99B 3.71B 2026-03
Gilead Sciences USD 5.06B 314M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Kangmei Pharma CNY 2.92B 228.09M 2026-03
Knight Therapeutics CAD 183M 7.46M 2025-12
Laboratorios Farma EUR 143.38M 16.93M 2023-12
Malin Corporation EUR 500K 300K 2024-12
Medical Developments International AUD 7.48M 174K 2025-12
Merck USD 12.21B 435M 2026-03
Neuren Pharmaceuticals AUD 26.54M 5.83M 2025-12
Novartis USD 9.6B 2.69B 2026-03
Organigram Holdings CAD 53.39M 3.45M 2026-03
Organon & Co USD 1.49B 108M 2026-06
Ovoca Bio EUR 53K 14K 2025-12
Pharma Mar EUR 58.06M 6.87M 2026-06
Qiagen NV USD 398.35M 1.73M 2026-06
Sartorius EUR 381.2M 14.6M 2026-06
Sino Biopharmaceutical CNY 8.45B 3.18B 2025-06
Tilray USD 109.07M 2M 2025-09
Zealand Pharma A/S 259M 81M 2026-03